Company news
CDT Equity Inc. news in 2025
CDT Equity Inc.'s news releases, calls and decks from 2025, newest first.
CDT Equity Increases Bitcoin Holding
October 16, 2025
CDT Equity Inc. Announces Reverse Stock Split
October 9, 2025
CDT Board Authorizes Adoption of Cryptocurrency Treasury Reserve Strategy
September 2, 2025
CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy
August 26, 2025
Conduit to Change Name to CDT Equity Inc.
August 5, 2025
Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries
July 6, 2025
Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health
June 4, 2025
Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market
May 22, 2025
Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
May 21, 2025
Conduit Pharmaceuticals Inc. Announces Reverse Stock Split
May 16, 2025
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
May 9, 2025
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
May 8, 2025
Conduit Pharmaceuticals Announces Leadership Changes
April 16, 2025
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects
April 11, 2025
Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program
April 10, 2025
Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization
April 7, 2025
Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
March 31, 2025
Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904
March 19, 2025
Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel
March 6, 2025
Conduit Progresses Phase II of its AI Initiative with Sarborg
February 20, 2025
Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model
February 12, 2025
Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note
February 10, 2025
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development
February 6, 2025
Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence
January 27, 2025
Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline
January 21, 2025